These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30147135)

  • 1. Implications of Statin Use on Vasopressor Therapy in the Setting of Septic Shock.
    McPheeters CM; Wiedmar JA; Pinkston CM; Weant KA
    Hosp Pharm; 2018 Jun; 53(3):152-156. PubMed ID: 30147135
    [No Abstract]   [Full Text] [Related]  

  • 2. Continuation of Statin Therapy and Vasopressor Use in Septic Shock.
    Zechmeister C; Hurren J; McNorton K
    Ann Pharmacother; 2015 Jul; 49(7):790-5. PubMed ID: 25896127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of statins on the clinical outcomes of patients with sepsis.
    Goodin J; Manrique C; Dulohery M; Sampson J; Saettele M; Dabbagh O
    Anaesth Intensive Care; 2011 Nov; 39(6):1051-5. PubMed ID: 22165357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Chronic Antihypertensives on Vasopressor Dosing in Septic Shock.
    DeMott JM; Patel G; Lat I
    Ann Pharmacother; 2018 Jan; 52(1):40-47. PubMed ID: 28799416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The incidences of organ dysfunction in the early resuscitation of severe sepsis and septic shock patients:a retrospective analysis].
    Wan L; Liao G; Wan X; Huang Y; Huang Q
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2016 May; 28(5):418-22. PubMed ID: 29920036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Sepsis and Mortality With Prior Exposure of HMG-COA Reductase Inhibitors in a Surgical Intensive Care Population.
    Schurr JW; Wu W; Smith-Hannah A; Smith CJ; Barrera R
    Shock; 2016 Jan; 45(1):10-5. PubMed ID: 26674450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.
    Whitson MR; Mo E; Nabi T; Healy L; Koenig S; Narasimhan M; Mayo PH
    Chest; 2016 Jun; 149(6):1380-3. PubMed ID: 26953217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to vasopressor initiation and organ failure progression in early septic shock.
    Black LP; Puskarich MA; Smotherman C; Miller T; Fernandez R; Guirgis FW
    J Am Coll Emerg Physicians Open; 2020 Jun; 1(3):222-230. PubMed ID: 33000037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Septic shock with no diagnosis at 24 hours: a pragmatic multicenter prospective cohort study.
    Contou D; Roux D; Jochmans S; Coudroy R; Guérot E; Grimaldi D; Ricome S; Maury E; Plantefève G; Mayaux J; Mekontso Dessap A; Brun-Buisson C; de Prost N
    Crit Care; 2016 Nov; 20(1):360. PubMed ID: 27816060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CT-proAVP IS NOT A GOOD PREDICTOR OF VASOPRESSOR NEED IN SEPTIC SHOCK.
    Laribi S; Lienart D; Castanares-Zapatero D; Collienne C; Wittebole X; Laterre PF
    Shock; 2015 Oct; 44(4):330-5. PubMed ID: 26196839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Response to Third-Line Angiotensin-II vs Epinephrine in Septic Shock: A Propensity-Matched Cohort Study.
    Blankenship CR; Betthauser KD; Hencken LN; Maamari JA; Goetz J; Giacomino BD; Gibson GA
    Ann Pharmacother; 2024 Feb; ():10600280231226132. PubMed ID: 38303571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical studies of surviving sepsis bundles according to PiCCO on septic shock patients].
    Lu N; Zheng R; Lin H; Shao J; Yu J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 Jan; 26(1):23-7. PubMed ID: 24506852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversies in Corticosteroid use for Sepsis.
    Long B; Koyfman A
    J Emerg Med; 2017 Nov; 53(5):653-661. PubMed ID: 28916121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of corticosteroids on arginine vasopressin-containing vasopressor therapy for septic shock: a case control study.
    Bauer SR; Lam SW; Cha SS; Oyen LJ
    J Crit Care; 2008 Dec; 23(4):500-6. PubMed ID: 19056013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
    Shankar-Hari M; Phillips GS; Levy ML; Seymour CW; Liu VX; Deutschman CS; Angus DC; Rubenfeld GD; Singer M;
    JAMA; 2016 Feb; 315(8):775-87. PubMed ID: 26903336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.
    Cruz DN; Antonelli M; Fumagalli R; Foltran F; Brienza N; Donati A; Malcangi V; Petrini F; Volta G; Bobbio Pallavicini FM; Rottoli F; Giunta F; Ronco C
    JAMA; 2009 Jun; 301(23):2445-52. PubMed ID: 19531784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Length of Vasopressors Infusion on Mortality.
    Kumar V; Srinivas S; Le TH; Barnes M; Kumar S; Redinski J
    Cureus; 2019 Aug; 11(8):e5336. PubMed ID: 31598443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydrocortisone Therapy in Catecholamine-Resistant Pediatric Septic Shock: A Pragmatic Analysis of Clinician Practice and Association With Outcomes.
    Nichols B; Kubis S; Hewlett J; Yehya N; Srinivasan V
    Pediatr Crit Care Med; 2017 Sep; 18(9):e406-e414. PubMed ID: 28658197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of patients with septic shock and high-dose vasopressor therapy.
    Auchet T; Regnier MA; Girerd N; Levy B
    Ann Intensive Care; 2017 Dec; 7(1):43. PubMed ID: 28425079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe sepsis and septic shock in patients with pre-existing non-cardiac pulmonary hypertension: contemporary management and outcomes.
    Tsapenko MV; Herasevich V; Mour GK; Tsapenko AV; Comfere TB; Mankad SV; Cartin-Ceba R; Gajic O; Albright RC
    Crit Care Resusc; 2013 Jun; 15(2):103-9. PubMed ID: 23931041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.